Stock Update (NYSE:ISR): IsoRay’s Cesium-131 Therapy Takes Center Stage AT Russia’s Neftyanik Hospital a Center of Excellence Providing Cutting Edge Cancer Treatments
Leading Russian Cancer Specialists Dr. Zyryanov and Dr. Oschepkov Performed the First Cesium Prostate Implants at Neftyanik Hospital in the City of Tyumen Richland, WA (January 13, 2015) – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that Urologist Alexander Zyryanov M.D. Ph.D. and… Read more »
Shares of IsoRay Inc opened today at $1.56 and are currently trading down at $1.509. ISR has a 1-year high of $3.77 and a 1-year low of $0.58. The stock’s 50-day moving average is $1.60 and it’s 200-day moving average is $2.02.
On the ratings front, IsoRay Inc has been the subject of a number of recent research reports. In a report published on December 1, analyst Jason Kolbert from Maxim Group reiterated a Buy rating on ISR, with a price target of $5, which represents a potential upside of 220.5% from where the stock is currently trading.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.